SG11201809931YA - 2-anilinopyrimidine derivatives as therapeutic agents for treatment of brain cancers - Google Patents
2-anilinopyrimidine derivatives as therapeutic agents for treatment of brain cancersInfo
- Publication number
- SG11201809931YA SG11201809931YA SG11201809931YA SG11201809931YA SG11201809931YA SG 11201809931Y A SG11201809931Y A SG 11201809931YA SG 11201809931Y A SG11201809931Y A SG 11201809931YA SG 11201809931Y A SG11201809931Y A SG 11201809931YA SG 11201809931Y A SG11201809931Y A SG 11201809931YA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- brain
- treatment
- michael
- pct
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662334830P | 2016-05-11 | 2016-05-11 | |
| PCT/US2017/032066 WO2017197062A1 (en) | 2016-05-11 | 2017-05-11 | 2-anilinopyrimidine derivatives as therapeutic agents for treatment of brain cancers |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201809931YA true SG11201809931YA (en) | 2018-12-28 |
Family
ID=60267544
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201809931YA SG11201809931YA (en) | 2016-05-11 | 2017-05-11 | 2-anilinopyrimidine derivatives as therapeutic agents for treatment of brain cancers |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US11052086B2 (zh) |
| EP (1) | EP3454860A4 (zh) |
| JP (1) | JP6908287B2 (zh) |
| KR (1) | KR20190006991A (zh) |
| CN (1) | CN109715164A (zh) |
| AU (1) | AU2017264839B2 (zh) |
| BR (1) | BR112018072887A2 (zh) |
| CA (1) | CA3023228A1 (zh) |
| CO (1) | CO2018012061A2 (zh) |
| EA (1) | EA201892311A1 (zh) |
| IL (1) | IL262801A (zh) |
| MX (1) | MX2018013602A (zh) |
| PH (1) | PH12018502360A1 (zh) |
| SG (1) | SG11201809931YA (zh) |
| TW (1) | TW201740951A (zh) |
| WO (1) | WO2017197062A1 (zh) |
| ZA (1) | ZA201807353B (zh) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2019501222A (ja) | 2016-01-07 | 2019-01-17 | シーエス ファーマテック リミテッド | Ｅｇｆｒチロシンキナーゼの臨床的に重要な変異体の選択的阻害薬 |
| EA201892661A1 (ru) | 2016-06-17 | 2019-07-31 | Бета Фарма, Инк. | Фармацевтические соли n-(2-(2-(диметиламино)этокси)-4-метокси-5-((4-(1-метил-1h-индол-3-ил)пиримидин-2-ил)амино)фенил)акриламида и их кристаллические формы |
| MX2019015177A (es) | 2017-06-16 | 2020-02-07 | Beta Pharma Inc | Formulaciones farmaceuticas de n-(2-(2-(dimetilamino)etoxi)-4-meto xi-5((4-(1-metil-1h-indol-3-il)pirimidin-2-il)amino)fenil)acrilam ida y las sales de ellas. |
| CN111100117B (zh) * | 2019-12-18 | 2021-02-19 | 上海倍而达药业有限公司 | 氨基嘧啶类化合物甲磺酸盐的晶型a及其制备方法和应用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7078409B2 (en) * | 2002-03-28 | 2006-07-18 | Beta Pharma, Inc. | Fused quinazoline derivatives useful as tyrosine kinase inhibitors |
| WO2008127707A1 (en) * | 2007-04-13 | 2008-10-23 | Dana Farber Cancer Institute, Inc. | Receptor tyrosine kinase profiling |
| TWI619713B (zh) * | 2010-04-21 | 2018-04-01 | 普雷辛肯公司 | 用於激酶調節的化合物和方法及其適應症 |
| EA201391626A1 (ru) | 2011-05-04 | 2014-03-31 | Ариад Фармасьютикалз, Инк. | Соединения для ингибирования клеточной пролиферации в egfr-стимулированных типах рака |
| JP5427321B2 (ja) * | 2011-07-27 | 2014-02-26 | アストラゼネカ アクチボラグ | ２−（２，４，５−置換−アニリノ）ピリミジン化合物 |
| WO2013106460A2 (en) * | 2012-01-09 | 2013-07-18 | University Of Washington Through Its Center For Commercialization | Compositions and methods for treating malignant astrocytomas |
| ES2715500T3 (es) | 2014-06-19 | 2019-06-04 | Ariad Pharma Inc | Compuestos de heteroarilo para la inhibición de la quinasa |
| WO2016029839A1 (zh) * | 2014-08-25 | 2016-03-03 | 四川海思科制药有限公司 | 一种（取代的苯基）（取代的嘧啶）胺基衍生物及其制备方法和药物用途 |
| CN105461695B (zh) | 2014-09-29 | 2018-03-27 | 齐鲁制药有限公司 | 嘧啶或三嗪衍生物及其制备方法和用途 |
| CN105085489B (zh) * | 2014-11-05 | 2019-03-01 | 益方生物科技（上海）有限公司 | 嘧啶或吡啶类化合物、其制备方法和医药用途 |
| EP3229798A4 (en) * | 2014-12-11 | 2018-05-30 | Beta Pharma, Inc. | Substituted 2-anilinopyrimidine derivatives as egfr modulators |
-
2017
- 2017-05-11 JP JP2018559217A patent/JP6908287B2/ja active Active
- 2017-05-11 US US16/300,949 patent/US11052086B2/en active Active
- 2017-05-11 WO PCT/US2017/032066 patent/WO2017197062A1/en unknown
- 2017-05-11 KR KR1020187035380A patent/KR20190006991A/ko not_active Application Discontinuation
- 2017-05-11 CA CA3023228A patent/CA3023228A1/en not_active Abandoned
- 2017-05-11 BR BR112018072887-0A patent/BR112018072887A2/pt not_active Application Discontinuation
- 2017-05-11 CN CN201780036188.7A patent/CN109715164A/zh active Pending
- 2017-05-11 AU AU2017264839A patent/AU2017264839B2/en active Active
- 2017-05-11 EP EP17796819.5A patent/EP3454860A4/en active Pending
- 2017-05-11 MX MX2018013602A patent/MX2018013602A/es unknown
- 2017-05-11 TW TW106115602A patent/TW201740951A/zh unknown
- 2017-05-11 EA EA201892311A patent/EA201892311A1/ru unknown
- 2017-05-11 SG SG11201809931YA patent/SG11201809931YA/en unknown
-
2018
- 2018-11-02 ZA ZA2018/07353A patent/ZA201807353B/en unknown
- 2018-11-05 IL IL262801A patent/IL262801A/en unknown
- 2018-11-07 CO CONC2018/0012061A patent/CO2018012061A2/es unknown
- 2018-11-09 PH PH12018502360A patent/PH12018502360A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP3454860A4 (en) | 2020-01-15 |
| ZA201807353B (en) | 2019-08-28 |
| EA201892311A1 (ru) | 2019-06-28 |
| US20190365755A1 (en) | 2019-12-05 |
| EP3454860A1 (en) | 2019-03-20 |
| TW201740951A (zh) | 2017-12-01 |
| MX2018013602A (es) | 2019-08-22 |
| JP2019514996A (ja) | 2019-06-06 |
| CN109715164A (zh) | 2019-05-03 |
| US11052086B2 (en) | 2021-07-06 |
| KR20190006991A (ko) | 2019-01-21 |
| JP6908287B2 (ja) | 2021-07-21 |
| AU2017264839B2 (en) | 2021-08-05 |
| CO2018012061A2 (es) | 2018-11-22 |
| AU2017264839A1 (en) | 2018-11-22 |
| IL262801A (en) | 2018-12-31 |
| BR112018072887A2 (pt) | 2019-03-06 |
| PH12018502360A1 (en) | 2019-03-25 |
| CA3023228A1 (en) | 2017-11-16 |
| WO2017197062A1 (en) | 2017-11-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201806515RA (en) | Eribulin-based antibody-drug conjugates and methods of use | |
| SG11201901126UA (en) | Combination therapy for cancer | |
| SG11201902938TA (en) | Compounds, devices, and uses thereof | |
| SG11201811564QA (en) | Methods of treating ovarian cancer | |
| SG11201806307YA (en) | Pyrazolo[1,5-a]pyrazin-4-yl derivatives as jak-inhibitors | |
| SG11201908532UA (en) | Macrocyclic compounds as ros1 kinase inhibitors | |
| SG11201809931YA (en) | 2-anilinopyrimidine derivatives as therapeutic agents for treatment of brain cancers | |
| SG11201806251WA (en) | Methods for treating er+, her2-, hrg+ breast cancer using combination therapies comprising an anti-erbb3 antibody | |
| SG11201908598PA (en) | Compounds useful in the treatment or prevention of a prmt5-mediated disorder | |
| SG11201810983PA (en) | Novel heterocyclic derivatives useful as shp2 inhibitors | |
| SG11201909963YA (en) | Methods for treating dravet syndrome | |
| SG11201408067YA (en) | Crystalline forms of a bruton's tyrosine kinase inhibitor | |
| SG11201808676RA (en) | Methods of treating pediatric cancers | |
| SG11201804901WA (en) | Compounds for the treatment of cancer and inflammatory disease | |
| SG11201805645QA (en) | Lsd1 inhibitors | |
| SG11201808237UA (en) | Substituted indole compound derivatives as dengue viral replication inhibitors | |
| SG11201805570WA (en) | Systems and methods for long term transdermal administration | |
| SG11201805828YA (en) | Method of treating c3 glomerulopathy | |
| SG11201804263PA (en) | Cancer treatment using 2-deoxy-2-fluoro-l-fucose in combination with a checkpoint inhibitor | |
| SG11201811559WA (en) | Cancer treatment combinations | |
| SG11201900558RA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201900546UA (en) | Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201900551WA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201805385QA (en) | Bromodomain and extra-terminal protein inhibitor combination therapy | |
| SG11201809788VA (en) | Nanoliposomal irinotecan for use in treating small cell lung cancer |